Knight Amends Normal Course Issuer Bid

Core Viewpoint - Knight Therapeutics Inc. has announced an amendment to its Normal Course Issuer Bid (NCIB), increasing the maximum number of common shares to be repurchased from 3,000,000 to 6,190,493, which represents approximately 10% of the public float as of August 8, 2025 [1]. Group 1: Share Repurchase Details - The company intends to repurchase common shares for cancellation through the Toronto Stock Exchange (TSX) or alternative Canadian trading systems, with the number and timing to be determined by the company [2]. - From August 22, 2025, to March 19, 2026, the company has already purchased 1,767,300 common shares at a weighted average price of $6.08 per share [2]. Group 2: Automatic Share Purchase Plan - Knight has amended its Automatic Share Purchase Plan (ASPP) with its broker to align with the increased number of common shares authorized for repurchase under the amended NCIB, allowing the broker to repurchase shares even during regulatory restrictions or blackout periods [3]. Group 3: Company Overview - Knight Therapeutics Inc. is a specialty pharmaceutical company based in Montreal, Canada, focused on acquiring, in-licensing, and commercializing pharmaceutical products for Canada and Latin America, with subsidiaries operating under United Medical, Biotoscana Farma, and Laboratorio LKM [4].